S
urvival of mature B cells depends critically on the TNFfamily cytokine B cell activating factor (BAFF, also known as BlyS) (1, 2) . Prosurvival signaling events induced by BAFF allow peripheral B cells to complete their maturation and accumulate in the peripheral lymphoid organs at physiological levels. BAFF is a ligand for three TNF receptor-family members, BAFF-R (also known as BR3), TACI, and BCMA [reviewed in (3) ]. Similar to BAFF-deficient mice, mice lacking BAFF-R expression display a strong reduction in late transitional and mature B-2 cell numbers (1, 2, (4) (5) (6) . In contrast, mice with individual or combined deficiencies of TACI and BCMA contain normal or even increased populations of mature B cells (6) (7) (8) . This genetic evidence suggests that BAFF-R is the receptor that mediates BAFF-dependent B cell survival.
The finding that BAFF activates alternative NF-B signaling, which requires IKK1 expression and promotes p100 processing to p52, suggested a link between BAFF stimulation and antiapoptotic gene activation as a mechanism for BAFF-mediated B cell survival (9) (10) (11) . This was further supported by the impaired survival of B cells with altered NF-B function (12, 13) . The solitary central role of NF-B in BAFF-mediated signaling has recently been challenged by the observation that B cells deficient in PKC␤ expression show impaired responses to BAFF but normal p100 processing to p52 (14) . Furthermore, BAFF treatment was shown to induce multiple signaling pathways, including Akt and Erk1/2 (14) (15) (16) . BAFF-induced Akt activation promotes an increase in the metabolic activity and protein synthesis, while sustained Erk1/2 activation leads to phosphorylation of the proapoptotic Bcl-2 family member Bim and prevents its accumulation (14) (15) (16) .
By using B cells that lack either BAFF-R or IKK1 expression, we show that BAFF-induced B cell growth is mediated by BAFF-R and requires IKK1 expression. We also show that late Akt and Erk1/2 phosphorylation are, like cell growth, dependent on BAFF-R and IKK1. These data identify IKK1, a molecule critical for alternative NF-B activation but also possessing other signaling functions (17, 18) , as a coordinator of multiple BAFF-R-mediated signaling pathways.
Results

BAFF-Mediated B Cell Size Increase Is Mediated by BAFF-R and
Requires IKK1. The TNF-family cytokine BAFF recognizes TACI and, to a lesser extent, BCMA (3), but it is its interaction with BAFF-R that is required for B cell survival (5, 6, 19, 20) . It was recently reported that treatment with BAFF promotes metabolic fitness of B cells as assayed by, among other things, increase in cell size (14, 16, 21) . To address the requirement of BAFF-R in BAFF-mediated cell size increase, we used B cells that lack BAFF-R expression but survive because of overexpression of the antiapoptotic molecule Bcl-2. BAFF induced a slight but reproducible increase in cell size of BAFF-R-sufficient (control, bcl-2tg) but not BAFF-R-deficient (baff-r Ϫ/Ϫ , bcl-2tg) B cells, showing that exposure to BAFF increases B cell size in a BAFF-R-dependent fashion (Fig. 1 A) .
To address the potential role of alternative NF-B activation in BAFF-mediated cell size regulation, we used IKK1-deficient B cells. Because constitutive ablation of IKK1 leads to perinatal death, we crossed mice harboring a conditional ikk1 allele (ikk1 f ) to mice that express Cre early in B cell development and recombine loxP-flanked alleles with high efficiency (mb1-cre) to generate mice with IKK1-deficient B cells. Consistent with previous results (22, 23) , B cell development in ikk1 f/f , mb1-cre (B cell ⌬IKK1 ) mice is apparently normal until the T1 stage, while further maturation is strongly blocked (M.S.-S. and K.R., unpublished results). Similar to BAFF-R deficiency (5, 6), transgenic expression of Bcl-2 partially rescues the survival defect of IKK1-deficient B cells [(22) and M.S.-S. and K.R., unpublished results], allowing us to obtain mature IKK1-deficient B cells. Western blot analysis confirmed the ablation of IKK1 protein in B cells from B cell ⌬IKK1 , bcl-2tg mice compared to control ikk1 f/f , bcl-2tg mice (Fig. 1B) . Furthermore, IKK1-deficient B cells express normal levels of BAFF-R (Fig. 1C) . The BAFF-induced increase in cell size of control, bcl-2tg B cells was not seen in BAFF-treated IKK1-deficient B cells (see Fig. 1 A) . In contrast, B cell antigen receptor (BCR) stimulation induced blast formation in the absence of BAFF-R or IKK1 expression [see supporting information (SI) Fig. S1 ], showing that these cells have the ability to grow. These data show that BAFF/BAFF-Rmediated cell size increase requires IKK1 expression.
BAFF Induces Akt and Erk1/2 Phosphorylation Through BAFF-R. BAFF treatment of B cells has been reported to induce Akt activation that initially occurs early (10 min to 1 h) and then again relatively late (24 h) (14, 16) . Of note, the kinetics (14, 16) and magnitude of early BAFF-mediated Akt activation vary significantly from no detectable activation after 10 min of BAFF stimulation (range of 0.6-to 1.3-fold relative to controls, n ϭ 5, K.L.O. and Y.S.) to an average of 10-fold (range of 2.6-to 25.8-fold relative to controls, n ϭ 11, A.P. and A.T.). Paradoxically, when early Akt activation in response to BAFF is observed, it occurs in the absence of BAFF-R yet is abrogated by the presence of soluble decoy BAFF-R in the incubation medium (Fig. S2) , which might indicate a role for TACI or BCMA. Given the central role of BAFF-R in regulation of B cell survival, it seems that the variable pattern of early Akt induction in response to BAFF in vitro may not mediate crucial functions in B cell physiology. In contrast, BAFF treatment for 24 h consistently induced Akt phosphorylation between 3-and 27-fold, which is entirely BAFF-R-dependent ( Fig. 2 A) , thus making this signaling event more likely to be related to B cell survival.
Craxton and colleagues showed that BAFF stimulation activates the Mek/Erk pathway in a B cell line (15) . We observed similar results in primary B cells, namely that BAFF stimulation for 24 h induces Erk1/2 phosphorylation, albeit less strongly than following BCR stimulation (Fig. S3) . We also found that BAFFinduced Erk1/2 phosphorylation depends on BAFF-R expression (Fig. 2B ). These data demonstrate that BAFF stimulates late Akt and Erk1/2 phosphorylation through BAFF-R and not TACI or BCMA.
BAFF-R-Induced Phosphorylation of Akt and Erk1/2 Is IKK1-Dependent.
The timing of BAFF-R-dependent Akt activation overlaps with an array of transcription and signaling events controlled by IKK1. To test a possible link between IKK1 and BAFF-Rmediated Akt and Erk1/2 activation, we used bcl-2tg IKK1-deficient B cells. In contrast to controls, IKK1-deficient B cells were unable to induce Akt phosphorylation in response to BAFF treatment (Fig. 3A) . Similar results were observed for BAFFinduced Erk1/2 phosphorylation (see Fig. 3A ). These effects were not because of a generalized defect in the PI-3K/Akt or Mek/Erk pathways in IKK1-deficient B cells, because BCR stimulation induced normal phosphorylation of Akt and Erk1/2 (see Fig. 3A ). These data suggest that BAFF/BAFF-R interaction induces Akt and Erk1/2 phosphorylation through IKK1-dependent signaling processes in B cells.
Our findings place IKK1 as a central upstream mediator of Akt and Erk1/2 activation in BAFF-R-mediated signaling events but do not exclude the possibility that BAFF/BAFF-R regulates B cell responses also through IKK1-independent signaling pathways. Indeed, we found that BAFF treatment of WT or bcl-2tg primary B cells induces MHC class II up-regulation (Fig. 3B and data not shown), while levels of other activation markers, such as CD69, CD80 or CD86 remain unchanged (see Fig. S1 and data not shown). The MHC class II up-regulation is completely dependent on BAFF-R but only partially dependent on IKK1 expression (see Fig. 3B ). In contrast, BCR stimulation leads to a similar increase of MHC class II and CD69 expression in BAFF-R-or IKK1-deficient and control bcl-2tg B cells (see Fig.  S1 ). The IKK1-independent signaling pathways from BAFF-R that mediate increased MHC class II expression are not known but may include the canonical NF-B signaling pathway (24) . (1, 2, 14, 16) , and genetic evidence strongly supports the notion that BAFF promotes B cell survival through only one of its three receptors, BAFF-R (1, 2, 4-8). We now show that the same is true for BAFF-dependent regulation of B cell growth. The PI-3K/Akt pathway plays an important role in regulating cellular metabolism and growth by activating the mammalian target of rapamycin (mTOR). The importance of the PI-3K/Akt/mTOR pathway in regulating B cell size in response to BAFF is highlighted by the findings that PKC␤-deficient B cells show impaired Akt phosphorylation and no increase in cell size in response to BAFF (14) . In addition, the mTOR inhibitor rapamycin partially blocks BAFF-mediated rescue of WT B cells from atrophy (16) . We found that BAFFinduced Akt phosphorylation is, indeed, mediated by BAFF-R. Furthermore, we found that IKK1 is an essential signaling molecule upstream of the PI-3K/Akt pathway in response to BAFF and that BAFF treated IKK1-deficient B cells are unable to grow. BAFF-R regulates both BAFF-induced survival and growth of B cells, but the downstream signaling requirements for these effects are not the same. Although, as noted, blocking the activation of PI-3K/Akt/mTOR is sufficient to inhibit growth, BAFF-induced B cell survival under the same conditions is relatively unaffected (14, 16) unless the B cells are also deficient for Pim2 expression, in which case BAFF is unable to promote B cell survival (16) . Pim2 is a target of alternative NF-B signaling and, as such, is induced in response to BAFF in an IKK1-dependent manner (11) . Thus, the requirement of IKK1 expression for both BAFF-induced Pim2 expression and activation of the PI-3K/Akt pathway might explain the defective survival of IKK1-deficient B cells in response to BAFF (11) . In addition, we found that IKK1 expression is required for Erk1/2 phosphorylation in response to BAFF-R signaling. Both the Akt and Erk pathways have been shown to negatively regulate the levels of the proapoptotic molecule Bim in B cells; Akt activation represses Bim expression (25) , while Erk activation promotes Bim protein turnover (15) . BAFF mediated NF-B activation also activates transcription of antiapoptotic Bcl-2 family members (9, 16, 24, (26) (27) (28) . BAFF-R signaling may thus promote B cell survival in an IKK1-dependent manner by setting the levels of pro-and antiapoptotic molecules in favor of survival by regulating multiple downstream signaling pathways.
Discussion
BAFF protects B cells from atrophy and provides survival signals to B cells in vivo and in vitro
Although the data presented here place IKK1 upstream of the Akt and Erk pathways in response to BAFF-R-mediated signaling, we do not know how IKK1 functions to activate the Akt and Erk pathways. One possibility is that IKK1 induces (or represses) downstream NF-B-dependent targets responsible for a second wave of signal transduction via the Akt and Erk pathways. Alternatively, IKK1 may signal more directly in a manner independent of its role in NF-B activation or function independent of its kinase activity. Interestingly, we found that at least one BAFF-induced response, namely up-regulation of MHC class II expression, depends on BAFF-R but largely independent of IKK1 expression. In all other tested cases, however, IKK1 serves as a major coordinator of signal transduction downstream of BAFF-R that regulates BAFF-induced B cell survival and growth.
Methods
Mouse Strains. C57BL/6, baff-r Ϫ/Ϫ (5), ikk1 f/f (29) , mb1-cre (30) and E-Bcl2 (31) mice were bred and maintained in specific pathogen free conditions. All mouse protocols were approved by the Harvard University and the Immune Disease Institute Institutional Animal Care and Use Committees.
Cell Purification and Stimulation. B cells were purified from spleen suspensions after red blood cell lysis by depleting CD43 positive cells with magnetic beads (Miltenyi). Purity was assayed by FACS and found to be Ͼ90% CD19 positive. B cells were cultured at 37°C for 1 to 3 h in 1% FCS B cell culture media [DMEM supplemented with 1% FCS (Biowhittacker), 10-mM hepes, 2-mM Lglutamine, 1-mM sodium pyruvate, 1ϫ penicillin/streptomycin, 1ϫ nonessential amino acids (Cellgro), and 50-M ␤-mercaptoethanol] before stimulation with 200-ng/ml recombinant human BAFF (kindly provided by Biogen), 25-ng/ml recombinant murine BAFF (R&D Systems) or 50-g/ml goat F(abЈ)2 antimouse IgM (Jackson Immunoresearch) in PBS for the indicated amount of time. Equal volumes of PBS were added to controls. Cells were harvested on ice and either stained or washed with ice-cold PBS before lysis. For some experiments (see Fig. S2 ), mature B cells were purified from spleen and lymph nodes by CD43 depletion followed by CD62L enrichment (Miltenyi). Purified B cells were preincubated overnight in B cell medium containing 10% FCS to reduce the background BAFF signaling caused by endogenous BAFF in vivo (9) . After preincubation, live cells were separated over a Ficoll gradient (Cedar Lanes). Cells were resuspended in culture medium and stimulated with BAFF (25-ng/ml recombinant murine BAFF or 200-ng/ml recombinant human BAFF) diluted in culture medium or an equal volume of culture medium without BAFF for control samples. We found that recombinant murine BAFF (R&D Systems) consistently caused stronger BAFF-mediated cell survival and growth compared to recombinant human BAFF (Biogen) (data not shown). Immunoblot Analysis. Whole-cell lysates were prepared in lysis buffer [40-mM Tris (pH 7.6), 150-mM NaCl, 2-mM EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1ϫ EDTA-free protease inhibitor mixture (Roche), 1-mM PMSF, 5-mM NaF, 0.5 M, 1-mM Na3VO4]. The protein concentration was determined by detergent-compatible protein assay kit (Bio-Rad). Equal amounts of protein were separated by SDS/PAGE and transferred to PVDF membranes (Millipore). The membranes were immunoblotted with indicated antibodies. Antibodies used here are phospho-Akt (S473), Akt, phospho-Erk1/2, Erk1/2 (Cell Signaling), IKK1 (Imgenex), and ␤-actin (Sigma-Aldrich).
